Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | DRD3 | P35462 | 5/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843699 | 0.93 | DRD2 (0.46) | DRD2DRD3CHRM2CHRM1 | |
| SCHEMBL4484004 | 0.92 | CACNA1I (0.52) | CACNA1IDRD2DRD3 | |
| SCHEMBL3855089 | 0.89 | FFAR4 (0.47) | FFAR4DRD2DRD3CHRM2CHRM1 | |
| SCHEMBL3844681 | 0.88 | FFAR4 (0.47) | FFAR4CACNA1IDRD2DRD3 | |
| SCHEMBL3850625 | 0.87 | DRD2 (0.49) | FFAR4CACNA1IDRD2DRD3LMNA | |
| SCHEMBL3852930 | 0.87 | DRD2 (0.49) | FFAR4CACNA1IDRD2DRD3 | |
| SCHEMBL3846127 | 0.85 | CHRM4 (0.48) | DRD2DRD3CHRM2CHRM1 | |
| SCHEMBL3848755 | 0.85 | DRD2 (0.45) | DRD2DRD3DRD1CHRM2CHRM1 | |
| SCHEMBL3852933 | 0.84 | DRD2 (0.53) | DRD2DRD3MAPT | |
| SCHEMBL3844427 | 0.84 | DRD2 (0.57) | CACNA1GDRD2DRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | claimed |
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | claimed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | claimed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | FFAR4 506/4885CACNA1I 1623/4885CACNA1G 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.